U.S. Health Secretary Robert F. Kennedy Jr. made the announcement Wednesday, June 25, in a pre-recorded video played at Gavi's pledging summit in Brussels. He accused Gavi of neglecting vaccine safety while pushing aggressive immunization programs, including the Wuhan coronavirus (COVID-19) and the DTP (diphtheria-tetanus-pertussis) vaccines.

"When the science was inconvenient, Gavi ignored the science," Kennedy said in the video. The longtime advocate for vaccine safety reforms referenced a 2017 study that suggested the DTP vaccine may be linked to higher infant mortality in girls.

He demanded transparency and evidence-based decision-making before Washington resumes contributions. "Until that happens, the U.S. won't contribute more to Gavi," the health secretary reiterated. Kennedy's stance marks a turning point in challenging what he calls "unaccountable and opaque policymaking" in global health.

The decision throws into question the future of global vaccination efforts, particularly concerning the controversial DTP vaccine. It was discontinued in Western nations in the 1990s following reports of severe adverse effects, including brain damage and death. While the DTP injection is no longer used in the West, it remains widely administered in Africa and other low-income regions.

Gavi and other globalist organizations continue promoting this dangerous injection, which isn't surprising given the organization's ties to bigger globalist entities. It receives funding from the Bill and Melinda Gates Foundation, and is aligned with the World Health Organization (WHO).

Is Gavi saving lives or demanding compliance?

Gavi responded by defending its reliance on WHO recommendations and independent expert reviews. It argued that these ensure vaccines are both "safe and effective."

"Having reviewed all available data, global immunization experts continue to recommend [the] DTP [vaccine] for infants in high-risk settings," the organization stated, emphasizing its role in reducing child mortality by half in supported countries since 2000. While Gavi acknowledged that the injection can cause temporary side effects such as fever, it insisted the trade-off is justified given limited healthcare access in impoverished regions.